[Treatment of vaso-occlusive crisis of sickle-cell disease with pentoxifylline].
Sickle-cell disease is usually complicated by vaso-occlusive attacks. A review of the case-histories of 26 patients permitted an analysis of 92 severe attacks. We compared the outcome of 52 attacks treated with hyperhydration associated with a modifying erythrocyte membrane agent (pentoxifylline), with 40 attacks treated with hyperhydration and other drugs. This result compares well the current knowledge of the rheologic mechanisms involved in vaso-occlusive attacks of sickle-cell disease.
Clerc
M
M
Unité d'hématologie pédiatrique, hôpital Debrousse, Lyon, France.
Doh-Egueli
D
D
Chapuis
F
F
Durin
A
A
Bertrand
Y
Y
Souillet
G
G
Philippe
N
N
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D013805:Theobromine / Q000031:analogs & derivatives*; D014652:Vascular Diseases / Q000188:drug therapy* / Q000209:etiology
D013805:Theobromine; D010431:Pentoxifylline
Traitement de la crise vaso-occlusive de la drépanocytose par la pentoxifylline.